homepage_cover_1Firm of Choice for the Most Difficult Legal Issues homepage_cover_2Cross-Border Capabilities with a China Edge NewsFangda advised AnHeart Therapeutics in Nuvation Bio’s acquisition in an all-stock transactionRead More InsightAntitrust China Annual Review 2023 Our annual review examines ten significant trends in China's antitrust landscape in 2023 and presents the forecasts for 2024.READ MORE Awards & RankingsThe Legal 500 Asia-Pacific 2024 Tier 1 RankingsChambers Greater China Region Guide 2023 Band 1 RankingsRead More